Fate Therapeutics, Inc.
FATE
$1.00
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -34.07M | -37.62M | -52.15M | -47.68M | -38.43M |
| Total Depreciation and Amortization | 3.28M | 3.33M | 4.81M | 4.61M | 4.72M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.13M | 5.85M | 21.45M | 10.52M | 5.19M |
| Change in Net Operating Assets | 73.00K | -5.37M | -1.91M | 3.13M | -3.79M |
| Cash from Operations | -24.59M | -33.81M | -27.80M | -29.42M | -32.31M |
| Capital Expenditure | -1.36M | -1.20M | -98.00K | -495.00K | -51.00K |
| Sale of Property, Plant, and Equipment | 122.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.83M | 43.87M | 22.91M | 25.96M | -53.32M |
| Cash from Investing | 19.59M | 42.67M | 22.82M | 25.46M | -53.37M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 0.00 | 0.00 | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -666.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.33M | -- | 3.13M | 0.00 | 1.94M |
| Cash from Financing | 1.33M | -- | 3.13M | 0.00 | 1.27M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.67M | 8.86M | -1.85M | -3.96M | -84.41M |